UISS for respiratory tract pathologies is a multi-compartment, polyclonal, stochastic patient-specific agent-based modelling simulator able to predict the response of the human immune system to the exposure to two deadly and dangerous respiratory tract pathogens i.e., Mycobacterium tuberculosis and SARS-CoV-2.


It predicts the outcome of new vaccination strategies for active tuberculosis and has already been validated with available data coming from clinical trials of two vaccines (RUTI and ID93+GLA-SE).


The consortium plans to complete its validation using anonymized data coming from patients enrolled in the STriTuVaD EC funded project, with a regulatory submission of qualification advice.